CAR-T Strategy in 2026: Scaling Autologous, Advancing Allogeneic

Join this thought leadership panel exploring how the CAR-T landscape continues to evolve as clinical and commercial experience grows. As autologous therapies expand into additional settings and allogeneic approaches continue to be studied, organizations are reassessing where to focus research, development, and operational efforts.

This discussion brings together perspectives from across the cell therapy ecosystem to examine key scientific, operational, and market considerations shaping CAR-T development in 2026 and beyond.

What you will learn:
~ Differences in the current use and development of autologous and allogeneic CAR-T therapies
~ Factors influencing manufacturing, supply chain, and clinical approaches
~ Regulatory, commercial, and operational considerations
~ Areas of ongoing development and uncertainty

Key topics include:
~ Modality strategy: roles of autologous vs allogeneic approaches
~ Manufacturing: scalability, consistency, and process control
~ Clinical development: expansion and durability considerations
~ Access: reimbursement and site-of-care factors
~ Regulatory & CMC: expectations and comparability
~ Supply chain: patient-specific vs off-the-shelf models
~ Collaboration: cross-sector partnership approaches

This panel provides perspectives on how organizations are approaching CAR-T strategy, including near-term priorities and longer-term considerations.